================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): January 15, 2003
Medicis Pharmaceutical Corporation
-------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-18443 52-1574808
(State or Other (Commission File Number) (IRS Employer
Jurisdiction of Identification No.)
Incorporation)
8125 North Hayden Road 85258-2463
Scottsdale, Arizona (Zip Code)
(Address of Principal Executive
Offices)
Registrant's telephone number, including area code: (602) 808-8800
N/A
------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
================================================================================
Item 5. Other Events
On January 15, 2003, Medicis Pharmaceutical Corporation, a
Delaware corporation ("Medicis" or the "Company") and Taro North America
("Taro") entered into a license and optional purchase agreement for four branded
prescription product lines for sale in the United States and Puerto Rico (the
"License Agreement"). The License Agreement is effective immediately and extends
through June 1, 2004, after which Taro may purchase the product lines, which are
used primarily in dermatology and pediatrics.
Under terms of the License Agreement, Taro is licensing four
brands from Medicis: TOPICORT(R) (desoximetasone), a topical corticosteroid used
for inflammatory skin diseases; A/T/S(R) (erythromycin), a topical antibiotic
used in the treatment of acne; OVIDE(R) (malathion), a pediculicide used in the
treatment of head lice; and PRIMSOL(R) (trimethoprim HCI), an antibiotic oral
solution for children with acute otitis media, or middle ear infections.
A copy of the press release appears as Exhibit 99.1 to this
Current Report and is incorporated herein by reference.
Item 7. Financial Statements and Exhibits
(a) Financial Statements of Business Acquired.
Not Applicable.
(b) Pro Forma Financial Information.
Not Applicable.
(c) Exhibits.
99.1 Copy of press release, dated January 15, 2003, issued by Medicis
Pharmaceutical Corporation and Taro Pharmaceutical Industries Ltd.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDICIS PHARMACEUTICAL CORPORATION
(Registrant)
Date: January 16, 2003 /s/ Mark A. Prygocki, Sr.
--------------------------------
Name: Mark A. Prygocki, Sr.
Title: Executive Vice President, Chief
Financial Officer, Corporate
Secretary and Treasurer
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------- --------------------
99.1 Copy of press release, dated January 15, 2003, issued by
Medicis Pharmaceutical Corporation and Taro Pharmaceutical
Industries Ltd.